TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319/WDR1.

Szczegóły
Abstrakt

Tytuł:: TNK2-AS1 upregulated by YY1 boosts the course of osteosarcoma through targeting miR-4319/WDR1.
Autorzy:: Yao W; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Yan Q; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Du X; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Hou J; Department of Bone and Soft Tumor, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Źródło:: Cancer science [Cancer Sci] 2021 Feb; Vol. 112 (2), pp. 893-905. Date of Electronic Publication: 2020 Dec 01.
Typ publikacji:: Journal Article
Język:: English
Imprint Name(s):: Publication: 2005- : Oxford : Wiley Publishing on behalf of the Japanese Cancer Association
Original Publication: Tokyo : Japanese Cancer Association, c2003-
MeSH Terms:: Bone Neoplasms/*genetics
Bone Neoplasms/*pathology
Gene Expression Regulation, Neoplastic/*genetics
Osteosarcoma/*pathology
Protein-Tyrosine Kinases/*metabolism
Animals ; Cell Line, Tumor ; Heterografts ; Humans ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Microfilament Proteins/genetics ; Microfilament Proteins/metabolism ; Osteosarcoma/genetics ; Protein-Tyrosine Kinases/genetics ; RNA, Long Noncoding/genetics ; RNA, Long Noncoding/metabolism ; Up-Regulation ; YY1 Transcription Factor/genetics ; YY1 Transcription Factor/metabolism
References:: JAAPA. 2018 Aug;31(8):15-19. (PMID: 29979330)
Cancer Sci. 2021 Feb;112(2):893-905. (PMID: 33164271)
Anticancer Res. 2017 Jan;37(1):81-85. (PMID: 28011477)
Cancer Lett. 2017 Oct 1;405:46-55. (PMID: 28642170)
Yonsei Med J. 2017 Nov;58(6):1092-1100. (PMID: 29047232)
Eur Rev Med Pharmacol Sci. 2017 Jun;21(12):2829-2834. (PMID: 28682435)
J Cell Physiol. 2018 Jan;234(1):950-957. (PMID: 30076726)
Sci Rep. 2018 Feb 13;8(1):2910. (PMID: 29440662)
Cancer Causes Control. 2015 Aug;26(8):1127-39. (PMID: 26054913)
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):185-192. (PMID: 30454892)
J Biomed Sci. 2017 Jul 18;24(1):46. (PMID: 28720111)
Oncogene. 2018 Nov;37(47):6166-6179. (PMID: 30002443)
Mol Ther. 2017 Oct 4;25(10):2383-2393. (PMID: 28750740)
Orthop Clin North Am. 2016 Jan;47(1):283-92. (PMID: 26614941)
Eur J Cancer. 2006 Oct;42(15):2420-4. (PMID: 16962318)
Curr Mol Pharmacol. 2020;13(2):144-149. (PMID: 31746301)
Biochem Biophys Res Commun. 2018 Nov 25;506(2):315-322. (PMID: 29056508)
Br J Cancer. 2020 Sep;123(6):1012-1023. (PMID: 32601462)
Biochem Biophys Res Commun. 2018 Jan 8;495(2):1822-1832. (PMID: 29229388)
Nucleic Acids Res. 2014 Jan;42(Database issue):D92-7. (PMID: 24297251)
Cell Death Dis. 2017 Dec 13;8(12):3211. (PMID: 29238035)
BMC Cancer. 2011 Nov 02;11:472. (PMID: 22047406)
J Cell Biochem. 2017 Dec;118(12):4772-4781. (PMID: 28519068)
Cancer Res. 2008 Mar 15;68(6):1797-808. (PMID: 18339860)
J Cell Mol Med. 2019 Nov;23(11):7289-7298. (PMID: 31468685)
DNA Cell Biol. 2017 Nov;36(11):947-958. (PMID: 28972861)
Adv Exp Med Biol. 2018;1094:97-108. (PMID: 30191491)
Int J Biol Sci. 2018 Jun 8;14(9):1067-1080. (PMID: 29989053)
Exp Cell Res. 2017 Oct 15;359(2):394-404. (PMID: 28822708)
Crit Rev Oncog. 2017;22(1-2):13-21. (PMID: 29604933)
Biochem Biophys Res Commun. 2018 Sep 5;503(2):1134-1140. (PMID: 29944887)
IUBMB Life. 2017 Nov;69(11):867-876. (PMID: 28960757)
United European Gastroenterol J. 2019 May;7(4):517-528. (PMID: 31065369)
Grant Information:: 182102410001 Department of Science and Technology of Henan Province; 2018.1-2019.12 Applied Research in the Diagnosis and Treatment of Osteosarcoma
Contributed Indexing:: Keywords: TNK2-AS1; WDR1; YY1; miR-4319; osteosarcoma
Substance Nomenclature:: 0 (MIRN4319 microRNA, human)
0 (MicroRNAs)
0 (Microfilament Proteins)
0 (RNA, Long Noncoding)
0 (WDR1 protein, human)
0 (YY1 Transcription Factor)
0 (YY1 protein, human)
EC 2.7.10.1 (Protein-Tyrosine Kinases)
EC 2.7.10.2 (TNK2 protein, human)
Entry Date(s):: Date Created: 20201109 Date Completed: 20210301 Latest Revision: 20210304
Update Code:: 20240105
PubMed Central ID:: PMC7893995
DOI:: 10.1111/cas.14727
PMID:: 33164271
: Czasopismo naukowe

Full Text Finder

Mounting research papers have suggested that long non-coding RNAs (lncRNAs) elicit important functions in the progression of osteosarcoma (OS). This study focused on the role of TNK2-AS1 in OS. TNK2-AS1 was powerfully expressed in OS tissues and cell lines. In addition, TNK2-AS1 downregulation inhibited proliferative, migratory, and invasive capacities while promoting apoptosis in OS cells. miR-4319 was removed by TNK2-AS1 and therefore TNK2-AS1 elevated WDR1 expression in OS cells. miR-4319 had an inhibitory influence on OS progression, while WDR1 was a contributor to OS progression. Rescue assays certified that TNK2-AS1 promoted malignant phenotypes in vitro and the growth in vivo of OS cells by upregulating WDR1. In depth, we found that YY1 accelerated the transcription of TNK2-AS1 in OS cells, and that its role in OS also depended on TNK2-AS1-regulated WDR1. In conclusion, TNK2-AS1 was positively modulated by YY1 and aggravated the development of OS by 'sponging' miR-4319 to elevate WDR1. The findings highlighted that TNK2-AS1 might be a promising target for the treatment of OS.
(© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)

Informacja